United Services Automobile Association Acquires Shares of 8,531 TG Therapeutics, Inc. $TGTX

Key Points

• United Services Automobile Association acquired a new stake in TG Therapeutics, purchasing 8,531 shares valued at approximately $340,000.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37.00, contributing to an average rating of "Moderate Buy" for the stock.
• In its latest earnings report, TG Therapeutics reported $0.17 EPS, missing estimates, but showed a 92.1% revenue increase compared to the same quarter last year.

United Services Automobile Association bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,531 shares of the biopharmaceutical company's stock, valued at approximately $340,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics during the fourth quarter valued at approximately $30,000. NBC Securities Inc. grew its holdings in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 433 shares during the last quarter. SVB Wealth LLC bought a new position in shares of TG Therapeutics in the 1st quarter valued at about $37,000. Finally, USA Financial Formulas bought a new position in TG Therapeutics during the 1st quarter worth approximately $57,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 20,852 shares of the company's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.64% of the company's stock.

TG Therapeutics Trading Up 2.0%

Shares of TGTX traded up $0.65 on Wednesday, reaching $32.64. 686,350 shares of the company's stock were exchanged, compared to its average volume of 2,448,995. The stock has a market capitalization of $5.18 billion, a P/E ratio of 88.51 and a beta of 1.88. The business has a 50 day moving average price of $32.23 and a two-hundred day moving average price of $35.71. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12 month low of $21.16 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same quarter in the previous year, the firm posted $0.04 earnings per share. TG Therapeutics's quarterly revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.